Last reviewed · How we verify
Alfredo Antonio Chetta — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Beclomethasone Dipropionate/Formoterol Fumarate | Beclomethasone Dipropionate/Formoterol Fumarate | phase 3 | Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination | Glucocorticoid receptor; beta-2 adrenergic receptor | Respiratory/Pulmonology |
Therapeutic area mix
- Respiratory/Pulmonology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Chiesi Farmaceutici S.p.A. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Sanofi · 1 shared drug class
- SkyePharma AG · 1 shared drug class
- Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Alfredo Antonio Chetta:
- Alfredo Antonio Chetta pipeline updates — RSS
- Alfredo Antonio Chetta pipeline updates — Atom
- Alfredo Antonio Chetta pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Alfredo Antonio Chetta — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alfredo-antonio-chetta. Accessed 2026-05-16.